gms | German Medical Science

27. Deutscher Krebskongress

Deutsche Krebsgesellschaft e. V.

22. - 26.03.2006, Berlin

Role Of Bortezomib In The Treatment Of Multiple Myeloma - First Results From a Representative Multicentre Treatment Survey in Germany (GER)

Meeting Abstract

  • corresponding author presenting/speaker Ralf Angermund - Medical Affairs, ORTHO BIOTECH, Neuss, Deutschland
  • W. Knauf - Onkologische Gemeinschaftspraxis, Frankfurt
  • M. Freund - Universitätsklinikum, Rostock
  • M. R. Nowrousian - Universitätklinikum, Essen
  • H. Einsele - Universitätklinikum, Wuerzburg
  • H. Goldschmidt - Universitätklinikum, Heidelberg
  • W. E. Berdel - Universitätklinikum, Muenster
  • W. Poenisch - Universitätklinikum, Leipzig
  • C. Straka - Klinikum Innenstadt, Ludwig-Maximilian-Universität, München
  • L. Kellermann - Oncology Information Service, Freiburg
  • S. Bammer - Medical Affairs, ORTHO BIOTECH, Neuss

27. Deutscher Krebskongress. Berlin, 22.-26.03.2006. Düsseldorf, Köln: German Medical Science; 2006. DocPO114

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter:

Veröffentlicht: 20. März 2006

© 2006 Angermund et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen ( Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.



Background: Bortezomib (Velcade®) (Vel) was approved in GER for Multiple Myeloma in April 2004 for treatment after 2nd relapse. A representative multicentre treatment survey was performed to detect treatment behaviour in GER. The survey performed in 4th quarter 2004, based on data of 3rd quarter 2004.

Methods: The methods of this representative analysis was provided elsewhere (Freund et al). The data presented here are a subset of this analysis based on 59 sites and 500 patients.

Results: 278 male and 222 female patients, 56% at the time of analysis for decision on primary therapy, 25% for secondary treatment and 19% for further treatment were included in this analysis. The centres participating were 15% university hospitals (UH), 27% non-university hospitals with specialized (SH) and 19% without specialized (NSH) haematology department, and 39% office-based haematologists (OBH). Vel was selected as therapy in 10.4% of patients in total, (14% UH, 52% SH, 2% NSH and 32% OBH) mainly for treatment of > 3rd relapse (21%), followed by 2nd relapse (15%) and 1st relapse (8%). No use of Vel was detected as primary treatment. Within treatment 3rd relapse, Vel was the 2nd most frequently used drug after dexamethasone (dex) (21% and 47% respectively). Vel was most frequently planned as next therapy (53%) followed by dex (23%) and thalidomide (thal) (12%). After 2nd relapse (approved label at that time), Vel was used as 7th most frequent drug (15%) after dex, cyclophosphamide, melphalan, thal, adriamycine and vincristine. Planned further therapy for these patients was most frequently Vel (51%) followed by dex (19%), thal (20%) and bendamustine (14%). According to multivariate analysis Vel was mostly used by OBH following thal , cyclophosphamide and dex treatment. After 1st relapse (not approved at time of survey), Vel played a minor role (8% of chemotherapy used, ranked 10th) mainly in SH in younger patients below age 40 yrs. with concurrent diseases not qualifying for high dose chemotherapy after melphalan treatment.

Conclusion: New treatment options like Vel are quickly integrated into treatment behaviour in GER, mainly by use in OBH and within approved indication. According to planned treatment, Vel was seen at this early time point as most frequently planned further therapy in 2nd relapse indicating this drug s possibility to become a future treatment standard in heavily pretreated patients. Further surveys are planned.